Lantern Pharma announced that the FDA has granted fast track designation for investigational drug candidate, LP-184, for treatment of Glioblastoma.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks